PIPELINE WATCH: Eight Approvals, Seven Filings And Three Launches
Executive Summary
This week's Pipeline Watch, a snapshot of all the late-stage R&D and regulatory events in the pharma and biotech industries, is now available to view.
You may also be interested in...
Vectura Reaps Value From Pan-JAK Inhibitor For Severe Asthma
The UK’s Vectura plc is gaining value from its back catalog of novel compounds through licensing its pan-JAK inhibitor, VR588, to a US start-up, the venture capital-backed Kinaset Therapeutics.
Pipeline Watch: Phase III Starts In RSV Prophlyaxis, Dry Eye Disease
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Jefferies' Survey Predicts M&A Rebound In 2021
An upturn in M&A activity across the whole healthcare sector is expected in 2021, with the COVID-19 pandemic and the associated development of a vaccine shining a light on the sector, says a recent survey by Jefferies.
Need a specific report? 1000+ reports available
Buy Reports